DINAMIQS

DINAMIQS is an active Swiss-based contract development and manufacturing organization specializing in the design, process development, analytics, and GMP-scale production of viral vectors—primarily AAV and lentiviral—for cell and gene therapy applications. The company operates advanced R&D labs in Zurich’s Bio-Technopark with pilot-scale equipment and is building a cGMP facility capable of up to 1,000L production capacity. It was acquired by Siegfried in May 2023 but continues to operate under its own name as an independent venture within the group[2][3][5]. No clinical results are reported as it does not run its own drug pipeline.